Familial Pancreatic Adenocarcinoma

Hematology/Oncology Clinics of North America

Volumn 29, Issue 4, 2015, Pages 641-653

  Petersen, Gloria M ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Familial risk; Genetic susceptibility; Genetic testing; Risk assessment and management

Indexed keywords

ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ATM GENE; CANCER PATIENT; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SUSCEPTIBILITY; CDKN2A GENE; CLUSTER ANALYSIS; EVIDENCE BASED MEDICINE; FAMILIAL CANCER; FAMILY HISTORY; FAMILY STUDY; FIRST DEGREE RELATIVE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERMLINE MUTATION; HIGH RISK PATIENT; HUMAN; MISMATCH REPAIR; NEXT GENERATION SEQUENCING; ONSET AGE; PALB2 GENE; PANCREAS ADENOCARCINOMA; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRSS1 GENE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SEX; SMOKING; SPINK2 GENE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CARCINOMA; GENETIC PREDISPOSITION; GENETICS; PANCREATIC NEOPLASMS; RISK FACTOR;

ADENOCARCINOMA; CARCINOMA; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; PANCREATIC NEOPLASMS; PRECISION MEDICINE; RISK FACTORS;

EID: 84938209362     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.04.007     Document Type: Review

References (57)

1. American Cancer Society Cancer facts & figures 2013, American Cancer Society, Atlanta (GA), Available at:. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf.
2. American Cancer Society Cancer facts & figures 2015, American Cancer Society, Atlanta (GA), Available at:. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
3. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004, 4(10):769-780.
4. Hemminki K., Rawal R., Chen B., et al. Genetic epidemiology of cancer: from families to heritable genes. Int J Cancer 2004, 111(6):944-950.
5. Antoniou A.C., Easton D.F. Models of genetic susceptibility to breast cancer. Oncogene 2006, 25(43):5898-5905.
6. Ghadirian P., Simard A., Baillargeon J. Cancer of the pancreas in two brothers and one sister. Int J Pancreatol 1987, 2(5-6):383-391.
7. Dat N.M., Sontag S.J. Pancreatic carcinoma in brothers. Ann Intern Med 1982, 97(2):282.
8. MacDermott R.P., Kramer P. Adenocarcinoma of the pancreas in four siblings. Gastroenterology 1973, 65(1):137-139.
9. Friedman J.M., Fialkow P.J. Familial carcinoma of the pancreas. Clin Genet 1976, 9(5):463-469.
10. Ehrenthal D., Haeger L., Griffin T., et al. Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 1987, 59(9):1661-1664.
11. Falk R.T., Pickle L.W., Fontham E.T., et al. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol 1988, 128(2):324-336.
12. Ghadirian P., Liu G., Gallinger S., et al. Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. Int J Cancer 2002, 97(6):807-810.
13. Fernandez E., La Vecchia C., D'Avanzo B., et al. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 1994, 3(3):209-212.
14. Silverman D.T., Schiffman M., Everhart J., et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999, 80(11):1830-1837.
15. Inoue M., Tajima K., Takezaki T., et al. Epidemiology of pancreatic cancer in Japan: a nested case-control study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Int J Epidemiol 2003, 32(2):257-262.
16. Schenk M., Schwartz A.G., O'Neal E., et al. Familial risk of pancreatic cancer. J Natl Cancer Inst 2001, 93(8):640-644.
17. Hassan M.M., Bondy M.L., Wolff R.A., et al. Risk factors for pancreatic cancer: case-control stud. Am J Gastroenterol 2007, 102(12):2696-2707.
18. Austin M.A., Kuo E., Van Den Eeden S.K., et al. Family history of diabetes and pancreatic cancer as risk factors for pancreatic cancer: the PACIFIC study. Cancer Epidemiol Biomarkers Prev 2013, 22(10):1913-1917.
19. Jacobs E.J., Chanock S.J., Fuchs C.S., et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer 2010, 127(6):1421-1428.
20. Shirts B.H., Burt R.W., Mulvihill S.J., et al. A population-based description of familial clustering of pancreatic cancer. Clin Gastroenterol Hepatol 2010, 8(9):812-816.
21. McWilliams R.R., Rabe K.G., Olswold C., et al. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 2005, 104(2):388-394.
22. Permuth-Wey J., Egan K.M. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 2009, 8(2):109-117.
23. Petersen G.M., de Andrade M., Goggins M., et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2006, 15(4):704-710.
24. Humphris J.L., Johns A.L., Simpson S.H., Australian Pancreatic Cancer Genome Initiative, et al. Clinical and pathologic features of familial pancreatic cancer. Cancer 2014, 120(23):3669-3675.
25. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343(2):78-85.
26. Klein A.P., Beaty T.H., Bailey-Wilson J.E., et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002, 23(2):133-149.
27. Banke M.G., Mulvihill J.J., Aston C.E. Inheritance of pancreatic cancer in pancreatic cancer-prone families. Med Clin North Am 2000, 84(3):677-690. x-xi.
28. Hruban R.H., Petersen G.M., Kern S., et al. Genetics of cancer of the pancreas: from genes to families. Surgical oncology clinics of North America, vol. 7, No. 1, pancreatic cancer 1998, 1-23. W. B. Saunders, New York. H.A. Pitt (Ed.).
29. Klein A.P., Brune K.A., Petersen G.M., et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004, 64(7):2634-2638.
30. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Available at: . Accessed May 22, 2015. http://seer.cancer.gov/.
31. Lynch H.T., Smyrk T., Kern S.E., et al. Familial pancreatic cancer: a review. Semin Oncol 1996, 23(2):251-275.
32. Klein A.P. Genetic susceptibility to pancreatic cancer. Mol Carcinog 2012, 51(1):14-24.
33. Roberts N.J., Jiao Y., Yu J., et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012, 2(1):41-46.
34. Grant R.C., Selander I., Connor A.A., et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 2014, 148(3):556-564.
35. Iqbal J., Ragone A., Lubinski J., Hereditary Breast Cancer Study Group, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2012, 107(12):2005-2009.
36. Zhen D.B., Rabe K.G., Gallinger S., et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer (FPC): a PACGENE study. Genet Med 2014, 10.1038/gim.2014.153.
37. Jones S., Hruban R.H., Kamiyama M., et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324(5924):217.
38. Eberle M.A., Pfutzer R., Pogue-Geile K.L., et al. A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am J Hum Genet 2002, 70:1044-1048.
39. Pogue-Geile K.L., Chen R., Bronner M.P., et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006, 3:e516.
40. Klein A.P., Borges M., Griffith M., et al. Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2009, 18(4):1328-1330.
41. van der Heijden M.S., Yeo C.J., Hruban R.H., et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003, 63(10):2585-2588.
42. Rogers C.D., van der Heijden M.S., Brune K., et al. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther 2004, 3(2):167-169.
43. Couch F.J., Johnson M.R., Rabe K., et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005, 65(2):383-386.
44. McWilliams R.R., Petersen G.M., Rabe K.G., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer 2010, 116(1):203-209.
45. Murphy K.M., Brune K.A., Griffin C., et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62(13):3789-3793.
46. Couch F.J., Johnson M.R., Rabe K.G., et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(2):342-346.
47. Stadler Z.K., Salo-Mullen E., Patil S.M., et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 2012, 118(2):493-499.
48. Lowery M.A., Kelsen D.P., Stadler Z.K., et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011, 16(10):1397-1402.
49. Vyas O., Leung K., Ledbetter L., et al. Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation. Anticancer Drugs 2015, 26(2):224-226.
50. National Institutes of Health. Available at: . Accessed May 22, 2015. http://ClinicalTrials.gov.
51. Verna E.C., Hwang C., Stevens P.D., et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010, 16(20):5028-5037.
52. Syngal S., Brand R.E., Church J.M., et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015, 110(2):223-262.
53. Fendrich V., Langer P., Bartsch D.K. Familial pancreatic cancer-status quo. Int J Colorectal Dis 2014, 29(2):139-145.
54. Canto M.I., Harinck F., Hruban R.H., International Cancer of Pancreas Screening (CAPS) Consortium, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013, 62(3):339-347.
55. Bartsch D.K., Gress T.M., Langer P. Familial pancreatic cancer-current knowledge. Nat Rev Gastroenterol Hepatol 2012, 9(8):445-453.
56. Langer P., Kann P.H., Fendrich V., et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009, 58(10):1410-1418.
57. Templeton A.W., Brentnall T.A. Screening and surgical outcomes of familial pancreatic cancer. Surg Clin North Am 2013, 93(3):629-645.